Fig. 1

Effect of BM-hMSC secretome on H295R cells and human PCOS theca cells. After 24 hours of treatment, a percentage of Ki67-positive cells, Annexin V-positive cells, and Annexin V+/7AAD double-positive cells in the BM-hMSC secretome-treated vs. control (basal media) H295R cells. b Relative mRNA expression of CYP17A1, CYP11A1, and DENND1A in BM-hMSC secretome-treated vs. control H295R cells. c Protein expression analysis of CYP17A1, CYP11A1,and DENND1A by western blot in BM-hMSC secretome-treated vs. control H295R cells. d Quantification of western blot by analyzing band intensity. e Relative mRNA expression of CYP17A1 in two different human PCOS theca cells after BM-hMSC secretome treatment vs. control (basal media). f Average protein expression level of CYP17A1 in human PCOS theca cells after BM-hMSC secretome treatment vs. control. g Testosterone secretion by H295R cells and human PCOS theca cells; BM-hMSC secretome vs. control group. h Relative gene expression of inflammatory marker IL1B and TNFA in BM-hMSC secretome-treated vs. control basal media in H295R cells. *p<0.05, **p<0.005, ***p<0.0005; NS, not significant. All graphs are presented as the mean ± SD (n=3). Statistical significances were determined by 2-way ANOVA or nonparametric T-test (Mann-Whitney test) using GraphPad Prism 9